Kymera Therapeutics, Inc.

For the period ended Jun 30, 2025. Filed Aug 11, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 11, 2025

KYMR$136.64-1.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

STOCKHOLDERS’ EQUITY

For the three months ended June 30, 2025 and 2024

(In thousands, except for share amounts)

Common Stock · AdditionalPaid in · Accumulated · AccumulatedOtherComprehensive · TotalStockholders’
Shares · Value · Capital · Deficit · Gain/(Loss) · Equity
Balance at March 31, 2024	61,353,146	$6	$1,292,283	$(579,309)	$(1,777)		$711,203
Exercise of stock options	74,318	—	630	—	—		630
Vesting restricted stock	80,694	—	—	—	—		—
Issuance of shares under employee stock purchase plan	64,225	—	1,134	—		1,134
Stock-based compensation expense	—	—	14,341	—	—		14,341
Unrealized loss on marketable securities	—	—	—	—	(322)		(322)
Net loss	—	—	—	(42,062)	—		(42,062)
Balance at June 30, 2024	61,572,383	$6	$1,308,388	$(621,371)	$(2,099)		$684,924
Balance at March 31, 2025	65,112,714	$7	$1,606,475	$(820,191)	$(58)		$786,233
Issuance of common stock and accompanying pre-funded warrants from June 2025 public offering, net of issuance costs of $13.5 million	5,044,500	—	237,294	—	—		237,294
Exercise of stock options	278,086	—	7,703	—	—		7,703
Vesting restricted stock	78,013	—	—	—	—		—
Issuance of shares under employee stock purchase plan	44,129	—	1,112	—	—		1,112
Stock-based compensation expense	—	—	15,415	—	—		15,415
Unrealized gain on marketable securities	—	—	—	—	337		337
Net loss	—	—	—	(76,614)	—		(76,614)
Balance at June 30, 2025	70,557,442	$7	$1,867,999	$(896,805)	$279		$971,480

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

For the six months ended June 30, 2025 and 2024

(In thousands, except for share amounts)

Common Stock · AdditionalPaid in · Accumulated · AccumulatedOtherComprehensive · TotalStockholders'
Shares · Value · Capital · Deficit · Gain/(Loss) · Equity
Balance at December 31, 2023	55,585,305	$6		$926,269		$(530,752)		$(552)		$394,971
Issuance of common stock and accompanying pre-funded warrants from public offering, net of issuance costs of $14.9 million	3,884,158	—		301,373		—		—		301,373
Issuance of common stock through At-The Market Sales Agreement, net of issuance costs of $1.2 million	1,519,453	—		48,740		—		—		48,740
Exercise of stock options	355,339	—		4,562		—		—		4,562
Vesting restricted stock	163,903	—		—		—		—		—
Issuance of shares under employee stock purchase plan	64,225	—		1,135		—			1,135
Stock-based compensation expense	—	—		26,309		—		—		26,309
Unrealized loss on marketable securities	—	—		—		—		(1,547)		(1,547)
Net loss	—	—		—		(90,619)		—		(90,619)
Balance at June 30, 2024	61,572,383	$6		$1,308,388		$(621,371)		$(2,099)		$684,924
Balance at December 31, 2024	64,890,193	$7		$1,591,707		$(754,610)		$(1,485)		$835,619
Issuance of common stock and accompanying pre-funded warrants from June 2025 public offering, net of issuance costs of $13.5 million	5,044,500		237,294		—		—		237,294
Exercise of stock options	353,738	—		8,237		—		—		8,237
Vesting restricted stock	224,882	—		—		—		—		—
Issuance of shares under employee stock purchase plan	44,129	—		1,112		—		—		1,112
Stock-based compensation expense	—	—		29,649		—		—		29,649
Unrealized gain on marketable securities	—	—		—		—		1,764		1,764
Net loss	—	—		—		(142,195)			(142,195)
Balance at June 30, 2025	70,557,442	$7		$1,867,999		$(896,805)		$279		$971,480

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.